Pathophysiology of heart failure: Changing perceptions

Pharmacotherapy

Volumn 16, Issue 2 II, 1996, Pages

  Patterson, J Herbert ^a,b   Adams Jr , Kirkwood E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; INOTROPIC AGENT; LOSARTAN; NEUROHORMONE; NITRATE; RENIN; VASODILATOR AGENT;

ADRENERGIC SYSTEM; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; FLUID RETENTION; HEART DILATATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART PRELOAD; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTRICTIVE CARDIOMYOPATHY; REVIEW;

CARDIAC OUTPUT, LOW; DIASTOLE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; SYSTOLE;

EID: 0029875302     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. American College of Cardiology/American Heart Association. American College of Cardiology/American Heart Association task force report. Guidelines for the evaluation and management of heart failure Circulation 1995,92:2764-84.
2. Rekha G, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s evolution of a major public health problem in cardiovascular medicine J Am Coll Cardiol 1993;22(4):2A-5
3. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
4. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993,71:3C-11.
5. Packer M. Pathophysiology of chronic heart failure. Lancet 1992,340:88-91.
6. Parmley WW. Principles in the management of congestive heart failure. In. Chatterjee K, Parmley WW, eds Cardiology: an illustrated text/reference. New York: Gower Medical, 1991:1.154-1.162.
7. Wynne J, Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical, and physical damage to the heart In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. Philadelphia. WB Saunders, 1992:1394-450.
8. SOLVD Investigators. Effect of enalaprii on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
9. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992;117:502-10
10. Smith TW, Braunwald E, Kelly RA. The management of heart failure. In: Braunwald E, ed Heart disease A textbook of cardiovascular medicine Philadelphia: WB Saunders, 1992:464-519
11. Dracup K, Baker DW, Dunbar SB. et al. Management of heart failure II Counseling, education, and lifestyle modification. JAMA 1994;272:1442-6.
12. Schlant RC, Sonnenblick EH. Pathophysiology of heart failure. In: Hurst JW, Schlant RC, Rackley CE, Sonnenblick EH, Wenger NK, eds. The heart, arteries, and veins. New York. McGraw-Hill, 1982:387-418.
13. LeJemtel TH, Katz SD, Sonnenblick EH. Peripheral circulatory response in cardiac failure. Hosp Pract 1991,26:73-80.
14. Stevenson LW, Tillisch JH. Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure Circulation 1986,74 1303-8
15. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J 1989;118:642-8.
16. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 1992,20.248-54.
17. Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine Philadelphia: WB Saunders, 1992:393-418.
18. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
19. Grinstead WC, Young JB. The myocardial renin-angiotensin system: existence, importance, and clinical implications Am Heart J 1992,123:1039-45
20. Hollenberg NK, Williams GH. The renin-angiotensin system in congestive heart failure. J Cardiovasc Med 1981;6:359-69
21. Timmermans P, Wong P, Chiu A, et al. Angiotensin II receptors and angiolensin II receptor antagonists. Pharmacological reviews. Am Soc Pharmacol Exp Ther 1993;45.205-48.
22. Burnett JC Jr. Atrial natriuretic factor, is it physiologically important? Circulation 1990;82.1523-4
23. Criteria Committee, New York Heart Association, Inc. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis, 6th ed Boston Little, Brown, 1964:114.
24. Braunwald E, Grossman W Clinical aspects of heart failure. In: Braunwald E, ed Heart disease A textbook of cardiovascular medicine Philadelphia: WB Saunders, 1992:444-63
25. Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction Clinical practice guideline no 11 Rockville, MD: Agency for Health Care Policy and Research, Public Health Service. U.S. Department of Health and Human Services, 1994.
26. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure. I Pharmacologic treatment JAMA 1994,272 1361-6.